Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores

Chen, Jonathan; Wu, Xian; Christos, Paul J.; Formenti, Silvia; Nagar, Himanshu

doi:10.1186/s13058-018-0957-3

Table 1 Patient demographics and characteristics

From: Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores

	All patients^a (N = 21,991)		No chemotherapy^b (N = 17,345)		chemotherapy^b (N = 4646)
Characteristic	n	%	n	%	n	%	p value^c
Facility type							< 0.001
Community cancer program	1914	8.7	1504	8.7	410	8.8
Comprehensive community cancer program	10,435	47.5	8379	48.3	2056	44.3
Academic/research program	7172	32.6	5666	32.7	1506	32.4
Other	2470	11.2	1796	10.4	674	14.5
Age category (years)							< 0.001
< 40	747	3.4	390	2.3	357	7.7
40–49	4735	21.5	3287	19.0	1448	31.2
50–59	7014	31.9	5380	31.0	1634	35.2
60–69	6823	31.0	5810	33.5	1013	21.8
70–79	2469	11.2	2288	13.2	181	3.9
80+	203	0.9	190	1.1	13	0.3
Race/ethnicity							0.004
Non-Hispanic White	17,628	80.2	13,982	80.6	3646	78.5
Non-Hispanic Black	1535	7.0	1189	6.9	346	7.5
Hispanic	898	4.1	685	4.0	213	4.6
Non-Hispanic Asian/Pacific	761	3.5	569	3.3	192	4.1
Other	1169	5.3	920	5.3	249	5.4
Primary payer							< 0.001
Not insured	341	1.6	248	1.4	93	2.0
Private insurance	14,567	66.2	10,994	63.4	3573	76.9
Medicaid	1172	5.3	881	5.1	291	6.3
Medicare	5479	24.9	4880	28.1	599	12.9
Other	432	2.0	342	2.0	90	1.9
Urban/rural							0.62
Metro counties	18,447	83.9	14,531	83.8	3916	84.3
Urban counties	2657	12.1	2120	12.2	537	11.6
Rural counties	354	1.6	275	1.6	79	1.7
Unknown	533	2.4	419	2.4	114	2.5
Charlson–Deyo score							< 0.001
0	19,070	86.7	14,980	86.4	4090	88.0
1	2540	11.6	2035	11.7	505	10.9
≥ 2	381	1.7	330	1.9	51	1.1
Grade							< 0.001
Well differentiated, differentiated, NOS	5723	26.0	4971	28.7	752	16.2
Moderately differentiated, moderately well differentiated, intermediate differentiation	12,305	56.0	9709	56.0	2596	55.9
Poorly differentiated	2780	12.6	1751	10.1	1029	22.2
Undifferentiated, anaplastic	13	0.1	8	0.1	5	0.1
Cell type not determined, not stated or not applicable, unknown primaries, high-grade dysplasia	1170	5.3	906	5.2	264	5.7
AJCC pathologic stage							< 0.001
T1C	15,766	71.7	12,827	74.0	2939	63.3
T2	6225	28.3	4518	26.1	1707	36.7
Lymphovascular invasion							< 0.001
Not present	17,155	78.0	13,795	79.5	3360	72.3
Present	2199	10.0	1507	8.7	692	14.9
Not applicable	14	0.1	10	0.1	4	0.1
Unknown	2623	11.9	2033	11.7	590	12.7
Type of surgery							< 0.001
Breast conservation	15,468	70.3	12,426	71.6	3042	65.5
Mastectomy	6521	29.7	4919	28.4	1602	34.5
Unknown	2	0.01	0	0.0	2	0.04
Margin status							0.01
Negative	21,189	96.4	16,745	96.5	4444	95.7
Positive	725	3.3	544	3.1	181	3.9
Unknown	77	0.4	56	0.3	21	0.5
Radiation therapy							< 0.001
None	6557	29.8	5032	29.0	1525	32.8
Beam radiation	14,116	64.2	11,183	64.5	2933	63.1
Other/unknown	1318	6.0	1130	6.5	188	4.1
Radiation treatment volume							< 0.001
No radiation treatment	6556	29.8	5031	29.0	1525	32.8
Breast or chest wall	14,829	67.4	11,875	68.5	2954	63.6
Breast/lymph nodes or chest wall/lymph nodes	470	2.1	350	2.0	120	2.6
Other	53	0.2	36	0.2	17	0.4
Unknown	83	0.4	53	0.3	30	0.7

AJCC American Joint Committee on Cancer, NOS not otherwise specified
^aCharacteristics for all patients who met inclusion criteria for this study
^bComparison of characteristics for the patients who did not receive chemotherapy to the patients who did receive chemotherapy
^cDifferences between these two populations on univariate analysis

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us